About us
TetraKit Technologies (“TetraKit”) was founded in 2021 as a spin-out from the University of Copenhagen. The key innovations in our company originate from the Herth lab at the University of Copenhagen’s Institute of Chemistry, a global leader in utilizing tetrazine ligation click chemistry in radiopharmaceutical applications.
Business Model
At TetraKit Technologies, we develop innovative radiopharmaceuticals in-house and collaborate with partners to broaden their application across oncology.
In-house drug development
We acquire high-potential targeting molecules through in-licensing and apply our proprietary TetraKit platform to radiolabel them with efficient halogen chemistry.
Read more
Platform partnership
In the platform partnership, the targeting molecule remains with the partner, while our proprietary TetraKit platform enables efficient radiolabeling.
Read more
